LCAR-HL30 is an engineered cell therapy given after a conditioning regimen of cyclophosphamide and fludarabine. It is studied in Hodgkin lymphoma and anaplastic large cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.